Reducing the side-effects of prostate hormone therapy with exercise

December 09, 2019

A prescription of short-term exercise for patients with advanced prostate cancer could help to reduce the side-effects of hormone therapy, according to new research from the University of East Anglia.

Researchers from the Norfolk and Norwich University Hospital (NNUH) and UEA led a trial which involved patients who were due to start androgen deprivation therapy (ADT).

Fifty patients took part in the research study, with half of the participants taking part in two supervised exercise sessions a week for three months at specialist exercise science facilities at UEA.

The trial aimed to reduce the adverse side-effects of hormone therapy such as weight gain and an increased risk of heart problems and assessed participants' health three months after their exercise programme.

The findings, which have been published in the British Journal of Urology International (BJUI), showed that the three month programme of aerobic and resistance training intervention prevented adverse changes in cardiopulmonary fitness and fatigue for those taking part in the trial.

Prof John Saxton, from UEA's Norwich Medical School, said: "Structured exercise programmes have much to offer people living with common cancers. Hormone treatments for prostate cancer are known to have undesirable side-effects, which increase a man's susceptibility to cardiovascular disease.

"This research shows that some of the harmful side-effects of hormone therapy are reduced in men who begin to exercise regularly around the same time that these drugs are prescribed.

"Our findings have important implications for the quality of prostate cancer survival," he added.

Wilphard Ndjavera, Clinical Fellow for Urology at NNUH, said: "All the patients really enjoyed the sessions and the results have suggested that exercise does work to reduce these harmful side effects of treatment. It is one of only two studies in the world to look at this."

"After the supervised exercise was withdrawn, differences in cardiopulmonary fitness and fatigue were not sustained, but the exercise group showed higher quality of life and reduced cardiovascular risk compared to the control group."

"These findings have important implications for clinicians concerned with the management of ADT-related side-effects."
'Exercise-induced attenuation of treatment side-effects in patients with newly diagnosed prostate cancer beginning androgen-deprivation therapy: a randomised controlled trial' is published in the British Journal of Urology International (BJUI).

For more information, visit

University of East Anglia

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to